Myriad's Presents Positive Clinical Data on HRD Test at SABCS 2013

By: Benzinga
Myriad Genetics (Nasdaq: MYGN ) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer. In this research study, Myriad's HRD test provided optimal prediction of
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.